Salarius Pharmaceuticals, Inc.
SLRX
$0.8777
$0.00040.05%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.11% | 51.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.45% | 47.91% | |||
| Operating Income | -15.45% | -47.91% | |||
| Income Before Tax | -16.78% | -50.59% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -16.78% | -50.59% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.78% | -50.59% | |||
| EBIT | -15.45% | -47.91% | |||
| EBITDA | -15.46% | -47.96% | |||
| EPS Basic | -1.39% | -33.61% | |||
| Normalized Basic EPS | -1.39% | -33.61% | |||
| EPS Diluted | -1.39% | -33.61% | |||
| Normalized Diluted EPS | -1.39% | -33.61% | |||
| Average Basic Shares Outstanding | 15.17% | 12.70% | |||
| Average Diluted Shares Outstanding | 15.17% | 12.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||